Eli Lilly (LLY.US) launches new Class 1 drug Phase III clinical trial in China
According to the Insight database, Brenipatide is the world's first GLP-1 product to initiate Phase III clinical trials for depression.
According to Golden Ten Data APP, on August 17, the official website for Drug Clinical Trial Registration and Information Disclosure showed that Eli Lilly (LLY.US) registered a phase III clinical trial of Brenipatide injection in adult participants with depression. The Insight database shows that Brenipatide is the world’s first GLP-1 product to initiate a phase III clinical trial for depression.
Screenshot source: Official website for Drug Clinical Trial Registration and Information Disclosure
Brenipatide is a GLP1R/GIPR dual agonist under development, and after tirzepatide, it is Eli Lilly’s second new GLP-1/GIP dual-target drug, with the most advanced trial globally at phase III and not yet approved for marketing. Besides depression, Eli Lilly has also initiated two phase III Brenipatide studies targeting alcohol use disorder. In addition, Eli Lilly is expanding other indications, such as bipolar disorder, asthma, nicotine dependence, schizophrenia, diarrhea-predominant irritable bowel syndrome, constipation-predominant irritable bowel syndrome, and chronic obstructive pulmonary disease.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The “outlier” in the AI capital expenditure frenzy: Apple (AAPL.US) keeps spending flat, accounting for less than 5% of sales
Apple continues to stand out among major tech peers, largely avoiding the aggressive wave of capital expenditure associated with artificial intelligence (AI) infrastructure.
Youth Employment Declines for 48 Consecutive Months: Behind the Semiconductor Boom, Young South Koreans Are Being Left Behind by the Times
In South Korea, the unemployment rate in October fell to a three-year low of 2.5%. However, the number of employed people decreased by 50,000, youth employment has declined for 48 consecutive months, and domestic demand remains weak.
Strategy (MSTR.US) Faces Potential Removal from MSCI Index, Passive Funds May Sell $2.8 Billion
MicroStrategy is expected to be removed from the MSCI Global Investable Market Index. JPMorgan estimates that passive funds may sell about $2.8 billion worth of shares, and if removed from multiple indexes simultaneously, the scale could reach up to $8.8 billion. Additionally, with BTC falling below its average cost of $75,456, the company’s stock price and financing capacity are under dual pressure.
Crypto prices
More
